TOP > 外国特許検索 > REGULATORY-T-CELL-INCREASING AGENT, CLOSTRIDIUM CLUSTER XIVa GROWTH PROMOTER, AND COMPOSITION FOR PREVENTION, TREATMENT, OR IMPROVEMENT OF INFLAMMATORY OR ALLERGIC DISEASE OR SYMPTOM

REGULATORY-T-CELL-INCREASING AGENT, CLOSTRIDIUM CLUSTER XIVa GROWTH PROMOTER, AND COMPOSITION FOR PREVENTION, TREATMENT, OR IMPROVEMENT OF INFLAMMATORY OR ALLERGIC DISEASE OR SYMPTOM NEW

外国特許コード F200010017
整理番号 (S2018-0606-N0)
掲載日 2020年1月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP018787
国際公開番号 WO 2019216422
国際出願日 令和元年5月10日(2019.5.10)
国際公開日 令和元年11月14日(2019.11.14)
優先権データ
  • 201862669680 (2018.5.10) US
発明の名称 (英語) REGULATORY-T-CELL-INCREASING AGENT, CLOSTRIDIUM CLUSTER XIVa GROWTH PROMOTER, AND COMPOSITION FOR PREVENTION, TREATMENT, OR IMPROVEMENT OF INFLAMMATORY OR ALLERGIC DISEASE OR SYMPTOM NEW
発明の概要(英語) Provided are: a regulatory-T-cell-increasing agent that contains an IL-17F inhibitor; a Clostridium cluster XIVa growth promoter that contains an IL-17F inhibitor; and a composition for the prevention, treatment, or improvement of inflammatory or allergic disease or symptoms that contains the regulatory-T-cell-increasing agent. The IL-17F inhibitor may be a substance that inhibits the interaction between IL-17F and the IL-17F receptors, a substance that inhibits the production or expression of IL-17F, or a substance that inhibits the expression of the IL-17F receptors.
従来技術、競合技術の概要(英語) BACKGROUND ART
IL-17F gene and the gene IL-17A, in both human and mouse of the present close to each other, their products is very high and the 50% amino acid homology, heterodimers are formed, the same receptor (Yao, Z. et al., 1995; Gaffen, S.L. et al., 2014; Iwakura, Y. et al., 2011). Any of these cytokines, bacterial infections and fungal infections host protection (Ishigame, H. et al., 2009; (Cai, Y. et al., 2011 the development of skin irritation Puel, A. et al., 2010), ; Hueber, W. et al., 2010; Martin, D.A. et al., 2013; Papp, K.A. et al., 2012) involved. Nevertheless, the IL-17A, and/or progression of autoimmune disease developing in the more important than IL-17F (Iwakura, Y. et al., 2011 play a role in; Ishigame, H. et al., 2009; Nakae, S. et al., 2003; Komiyama, Y. et al., 2006).
IL-17A and none of the IL-17F, TH17 cells, 3 type (ILC3) natural immune cells, a cell γ δ T, NKT cells, and CD8+ T are produced by the cells, some cells produce only one of these cytokines (Ishigame, H. et al., 2009; Yang, X.O. et al., 2008). For example, activated monocytes, mast cells, basophils, and mucosal epithelial cells, which produce only IL-17F (Ishigame, H. et al., 2009; Starnes, T. et al., 2001; Kawaguchi, M. et al., 2001). IL-17A is, cytokines and chemokines than IL-17F induce high activity. In addition, the IL-17A, lymphoid cells express high levels of IL-17 A receptor (IL-17RA) high affinity to, the IL-17F, predominantly non-hematopoietic cells express C IL-17 (IL-17RC) receptor with high affinity to (Ishigame, H. et al., 2009; Kuestner, R.E. et al., 2007). Therefore, the IL-17A and IL-17F, overlapping in the immune system has a distinct function.
Inflammatory bowel disease (IBD) is, diarrhea and weight loss and chronic inflammatory diseases of the intestines with, dextran sulfate sodium (DSS) and induced colitis is induced colitis cell CD25-CD45RBhiCD4 + T, a model of IBD. TH1 Cells, T cells in the pathogenesis of induced colitis suggesting that this model is protective (Powrie, F. et al., 1994), IL-17A (O'Connor, W., Jr. et al., 2009). IL-17A is, intestinal epithelial cells and required to maintain and tight (Lee, J.S. et al., 2015; Maxwell, J.R. et al., 2015), also, in cooperation with the epithelial repair FGF2 can be protected against induced colitis DSS (Song, X. et al., 2015) role. (Il17f - / -) Mice deficient in IL-17F DSS induced colitis (Il17a - / -) is resistant to missing (Yang, X.O. et al., 2008), IL-17A mouse is more sensitivity.
However, in the IL-17A IBD and functional differences of the mechanisms of the IL-17F has not been elucidated. In addition, other IBD inflammatory or allergic diseases or symptoms of the IL-17A for functional differences and IL-17F has not been elucidated.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO UNIVERSITY OF SCIENCE FOUNDATION
  • 発明者(英語)
  • IWAKURA, Yoichiro
  • TANG Ce
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close